Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04314895 · ClinicalTrials.gov registry record · Phase 2
Trial of NanoPac Intratumoral Injection in Lung Cancer
A Phase 2 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT04314895 is a Phase 2 study that has completed, run by NanOlogy. The registered enrollment target is 18 participants.
The verdict
NCT04314895, a Phase 2 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
Interventions
- DRUG NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2023-09-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04314895
The ClinicalTrials.gov registry entry for NCT04314895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NanOlogy, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension is the first listed.
NCT04314895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04314895 about?
NCT04314895 is a clinical study titled "Trial of NanoPac Intratumoral Injection in Lung Cancer". This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.
What is the current status of trial NCT04314895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-04-14. Estimated completion is 2023-09-26.
What interventions are being tested in trial NCT04314895?
The interventions under investigation include: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension (DRUG).
Who is sponsoring clinical trial NCT04314895?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.